News

Fund+ in the news
March 24, 2020

eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations

eTheRNA launches an international consortium and starts development of cross-strain protective CoV-2 mRNA vaccine for high risk populations   Niel, Belgium: eTheRNA Immunotherapies nv (‘eTheRNA’ or ‘The Company’), a clinical-stage company developing vaccines and immunotherapies from its proprietary mRNA TriMix platform, today announced that a consortium has been formed with North American and European partners […]

Read Post
March 19, 2020

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies

HORAMA Signs Exclusive License Agreement with Leiden University Medical Center Targeting CRB1 Gene Mutations to Treat Inherited Retinal Dystrophies Further expansion of HORAMA gene therapy portfolio to treat Inherited Retinal Dystrophies to lead to second clinical program by 2023 Paris (France) and Leiden (Netherlands), March 18, 2020 ‐ HORAMA SA, a French biotechnology company focusing […]

Read Post
March 13, 2020

Job opening at Fund+ / Internship

Job opening Internship Fund+ is seeking an Intern to support its team during a 3-6 month placement. We are looking for someone with passion for life sciences and startups and make the first step to develop a career in Venture Capital investments. Our purpose is to make long term investments in highly innovative, life science companies primarily active in […]

Read Post
March 13, 2020

Job opening at Fund+ / Senior Associate

Job opening Senior Associate Fund+ is seeking a Senior Associate who can contribute to the value creation of our investments. Our purpose is to make long term investments in highly innovative, life science companies primarily active in therapeutics, as well as companies developing diagnostics and medical devices, with strong long-term potential. The combination of our open-ended […]

Read Post
March 13, 2020

HORAMA strengthens its management team with the appointment of Rodolphe Clerval as Chief Business Officer (CBO)

HORAMA strengthens its management team with the appointment of Rodolphe Clerval as Chief Business Officer (CBO) Paris, France, March 11th, 2020 – HORAMA, a clinical stage gene therapy company in ophthalmology, today announced that Rodolphe Clerval has been appointed as Chief Business Officer (CBO). Rodolphe has a strong track record of executing strategic partnerships, business […]

Read Post
February 28, 2020

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers

iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers –  First patient enrolled in dose escalation portion of Phase 1/2 study of EOS-448, an antagonist anti-TIGIT antibody that enables antibody dependent cellular cytotoxicity (ADCC) – – ADCC-enabled TIGIT programs are progressing into pivotal trials –– – clinical data expected in […]

Read Post
February 18, 2020

Minoryx Therapeutics in the news

Minoryx Therapeutics in the news

Read Post
January 31, 2020

La Wallonie octroie 15 millions à iTeos

La Wallonie octroie 15 millions – iTeos

Read Post
January 9, 2020

Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD

Minoryx Therapeutics receives US FDA fast-track designation for leriglitazone in the treatment of X-ALD Leriglitazone (MIN-102), a novel, brain penetrant, orally bioavailable and selective PPARγ agonist, is currently in late-stage development for treatment of severe orphan CNS disorders, including X-ALD and Friedreich’s Ataxia. It previously received Orphan Drug Designation from EMA and FDA for both […]

Read Post
December 4, 2019

Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science

Novadip Biosciences to present data at 17th Annual Meeting of the International Federation for Adipose Therapeutics and Science Mont-Saint Guibert, Belgium, 4 December, 2019: Novadip Biosciences (“Novadip” or “the company”), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple product candidates, announces that it is presenting data in a series […]

Read Post
November 13, 2019

Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia

Minoryx Therapeutics receives Orphan Drug Designation from the European Commission for leriglitazone in the treatment of Friedreich’s Ataxia Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist Second Orphan Drug Designation granted by the European Commission for leriglitazone, in addition to X-linked adrenoleukodystrophy (X-ALD) Orphan Drug Status provides a number of […]

Read Post
November 13, 2019

Business Alliance between Promethera Biosciences SA and MEDIPAL HOLDINGS

Notice of Business Alliance between Promethera® Biosciences SA and MEDIPAL HOLDINGS – Bringing Innovative Liver-Focused Cell Therapies to Japanese Markets –   Promethera® Biosciences SA (“Promethera®“) and MEDIPAL HOLDINGS CORPORATION (“MEDIPAL”) today announced that they have entered into a business alliance agreement. In conjunction with today’s alliance, MEDIPAL has decided to increase its shareholdings in the […]

Read Post
October 28, 2019

EyeD Pharma CEO Melanie Mestdagt in the news

EyeD Pharma CEO Melanie Mestdagt in the news

Read Post
October 17, 2019

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics receives FDA Orphan Drug Designation for leriglitazone in Friedreich’s Ataxia   Leriglitazone (MIN-102) is a novel, brain penetrant, orally bioavailable and selective PPARγ agonist Second Orphan Drug Designation granted by the FDA for leriglitazone in addition to X-linked adrenoleukodystrophy (X-ALD) Potential for seven years of marketing exclusivity in the USA upon approval in […]

Read Post
October 16, 2019

Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson

Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson   SAN DIEGO, Oct. 15, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced the appointment of Tamar Howson, a highly seasoned life sciences executive, […]

Read Post
October 11, 2019

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis   – Milestone Achieved Nine Months Ahead of Initial Schedule; Top-Line Data Expected in Q3 2020 –   SAN DIEGO, Oct. 10, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, […]

Read Post
October 9, 2019

Minoryx: Un axe Espagne-Belgique pour sauter la barrière

Minoryx News Article: Un axe Espagne-Belgique pour sauter la barrière  

Read Post
October 8, 2019

Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia

Minoryx Therapeutics completes enrollment in FRAMES phase 2 trial with leriglitazone in Friedreich’s Ataxia Recruitment of 39 patients in multicenter European phase 2 trial completed ahead of schedule   Mataró, Barcelona, Spain and Charleroi, Belgium, October 8, 2019 – Minoryx Therapeutics, a company specializing in the development of innovative treatments for orphan central nervous system […]

Read Post
October 4, 2019

Novadip Biosciences – Belgische ‘biotechplasticine’ redt been vijfjarige

  Novadip Press Article: Belgische ‘biotechplasticine’ redt been vijfjarige

Read Post
October 2, 2019

Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference

Novadip Biosciences Presents Clinical Case Study on Next Generation Tissue Regeneration Therapy for Critical Size Bone Reconstruction at EORS Conference Study highlights potential benefit in rare pediatric orthopedic disorder   Mont-Saint-Guibert, Belgium, October 2, 2019: Novadip Biosciences (“Novadip” or “the company”), a clinical-stage biopharmaceutical company leveraging its unique tissue regeneration technology platform to generate multiple […]

Read Post
September 23, 2019

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019

FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 2019 Ghent, Belgium, 23 September 2019 – Confo Therapeutics, a pioneering biopharma company, today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in […]

Read Post
September 18, 2019

Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist   SAN DIEGO, Sept. 18, 2019 /PRNewswire/ — Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced dosing of the first healthy […]

Read Post
September 10, 2019

Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range

Immunic, Inc.’s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range   – Unblinded Data Review Committee Recommended Continuation of the Lowest, 10 mg Dose as well as the Highest, 45 mg Dose –   – […]

Read Post
July 3, 2019

Confo Therapeutics and DyNAbind announce drug discovery collaboration to identify novel GPCR-modulating compounds

Ghent, Belgium, and Dresden, Germany – 3 July 2019 – Confo Therapeutics, an emerging drug discovery company, and DyNAbind GmbH today announce a drug discovery collaboration on an undisclosed G-protein coupled receptor (GPCR). The collaboration will combine ConfoBodyTM-enabled GPCRs with DyNAbind’s Dynamic DNA-encoded Library for the discovery of small molecule GPCR-modulating compounds. Under the terms […]

Read Post
June 20, 2019

Confo Therapeutics receives €1.7 million grant from VLAIO

Ghent, Belgium, 20 June 2019 – Confo Therapeutics, an emerging drug discovery company, today announces that it has been awarded a €1.7 million grant from Flanders Innovation & Entrepreneurship (VLAIO). The grant will run over two years and will support one of the Company’s proprietary pre-clinical programs, targeting a neurological orphan indication. The grant will […]

Read Post